Human Embryonic Stem Cell Clinical Trials[edit] Introduction[edit]
The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients suffering from spinal cord injuries to participate in the trial. The company hoped that GRNOPC1, a product derived from human embryonic stem cells, would stimulate nerve growth in patients with debilitating damage to the spinal cord.[1] The trial began in 2010 after being delayed by the FDA because cysts were found on mice injected with these cells, and safety concerns were raised.[2]
In the United States, the FDA must approve all clinical trials involving newly developed pharmaceuticals. Researchers must complete an Investigational New Drug (IND) application in order to earn the FDAs approval. IND applications typically include data from animal and toxicology studies in which the drugs safety is tested, drug manufacturing information explaining how and where the drug will be produced, and a detailed research protocol stating who will be included in the study, how the drug will be administered and how participants will be consented.[3] Testing for new drugs must successfully go through three phases of research before a drug can be marketed to the public. In Phase I trials, the drugs safety is tested on a small group of participants. The drugs effectiveness is tested during Phase II trials with a larger number of participants. Phase III trials, involving 1,000- 3,000 participants, analyze effectiveness, determine side effects and compare the outcomes of the new drug to similar drugs on the market.[4] An additional phase, Phase IV, is included to continually gain information after a drug is on the market. Gerons IND application for the GRNOPC1 clinical trial, nearly 28,000 pages in length, was one of the most extensive applications ever to be submitted to the FDA.[2]
Before Geron could test GRNOPC1 in humans, tests in animals had to occur. At the University of California at Irvine, Dr. Hans Keirstead and Dr. Gabriel Nistor, credited with the technique used to develop oligodendrocytes from human embryonic stem cells, injected the cells into rats with spinal cord injuries. The condition of the rats improved after treatment.[5]
The first patient, identified in an article by the Washington Post as Timothy J. Atchison of Alabama, enrolled in the trial in October 2010. The patient was treated at the Shepherd Center in Atlanta, GA just two weeks after he sustained a spinal cord injury in a car accident. The Shepherd Center and six other spinal centers were recruited by Geron to participate in the clinical trial. The Washington Post reported that Atchison has begun to get some very slight sensation: He can feel relief when he lifts a bowling ball off his lap and discern discomfort when he pulls on hairs on some parts of his legs. He has also strengthened his abdomen. Atchison underwent therapy at the Shepherd Center for three months before returning home to Alabama.[6]
Although Geron initially aimed to enroll ten patients in the trial, only three additional patients were added after Atchison. As specified by Geron, eligible patients had to experience a neurologically complete spinal cord injury within seven to fourteen days prior to enrollment. In addition, patients had to be between the ages of 18 and 65 and could not have a history of malignancy, significant organ damage, be pregnant or nursing, unable to communicate or participate in any other experimental procedures. Participants received one injection of GRNOPC1 containing approximately 2 million cells. Even though the trial has officially ended, Geron will continue to monitor participants for fifteen years.[7]
Although no official results from the trial have been published, preliminary results from the clinical trial were presented at the American Congress of Rehabilitation Medicine (ACRM) conference in October 2011. None of the participants experienced serious adverse events, although nausea and low magnesium were reported. In addition, no changes to the spinal cord or neurological condition were found.[8]
After investing millions of dollars in the research leading up to this trial, Geron Corporation discontinued the study in November 2011 to focus on cancer research. John Scarlett, Gerons chief executive officer, said In the current environment of capital scarcity and uncertain economic conditions, we intend to focus our resources on advancing our two novel and promising oncology drug candidates.[9] The companys stocks fell dramatically to $1.50 per share from $2.28 per share when news of the trials discontinuation became public. A spokesperson for the company said that Geron would save money by ending the trial despite the loss in investors. Because many believed Gerons trial offered hope for advancing knowledge related to stem cells and their potential uses, there was disappointment in the scientific community when the trial was cut short. An article on Bioethics Forum, a publication produced by The Hastings Center, stated, "It is one thing to close a trial to further enrollment for scientific reasons, such as a problem with trial design, or for ethical reasons, such as an unanticipated serious risk of harm to participants. It is quite another matter to close a trial for business reasons, such as to improve profit margins."[10]
In 2013 Geron's stem cell assets were acquired by biotechnology firm BioTime, helmed by CEO Michael D. West, the founder of Geron and former Chief Scientific Officer of Advanced Cell Technology. BioTime indicated that it plans to re-start the embryonic stem cell-based clinical trial for spinal cord injury.[11]
Two clinical trials involving derivatives of human embryonic stem cells were approved in 2010. Advanced Cell Technology (ACT) located in Marlborough, Massachusetts, leads the trials aimed at improving the vision of patients with Stargardts Macular Dystrophy and Dry Age-Related Macular Degeneration. Originally, twelve patients were estimated to enroll at three hospitals in the U.S.; participating institutions included the Casey Eye Institute in Portland, Oregon, University of Massachusetts Memorial Medical Center in Worchester, Massachusetts, and the New Jersey Medical School in Newark, New Jersey.[12] Patients eyes were injected with retinal pigmented epithelial cells derived from human embryonic stem cells. While no definitive findings from this study have been produced, an article published in Lancet in January 2012 stated that preliminary findings appear to be promising. In this article, outcomes from two patients treated as part of the trial were discussed. During the trial, neither patients vision worsened, and no negative side effects were reported.[13]
Phase I/II clinical trials involving retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells, for the treatment of severe myopia were approved in February 2013.[14]
The FDA approved a phase I clinical trial with ViaCyte beta cells derived from human embryonic stem cell for the treatment of diabetes in August 2014.[15] The cells will be delivered in immunoprotective capsules and pre-clinical results in animal models showed remission of symptoms within a few months.[16] The company reported the successful transplantation of the cells in the first of the 40 patients that will be treated under the trial in late October 2014.[17]
As state funding for human embryonic stem cell research grows, t
here seems to be more support for state sponsored clinical trials. In 2010, California committed fifty million dollars to early-stage clinical trials. Although approved trials must take place in California, scientists are hopeful that this funding will bolster future research in the field.[18]
See the original post here:
Human embryonic stem cells clinical trials - Wikipedia ...
- ACT - Stem Cell Trial for AMD and Stargardt - Phase 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Excerpt from: "The Urban Wire" Internet Radio Podcast: FDA Oks embryonic stem cell trials for humans [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Advanced Cell Technology (ACT) AMD stem cell clinical phase [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Stem Cells Retina and cornea regeneration ACT Dr lanza - Advanced Cell Technology [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Spinal Patient Receives Stem Cells in First Experimental Treatment [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bloomberg: Geron, StemCells Rise 4% [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bringing Stem Cell Cures to the Clinic: UC Davis GMP Facility [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Researchers in California Show Results for Spinal Cord Injuries Using Embryonic Stem Cells [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bill Caldwell, Chairman [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT edmund vision stem cells program Advanced Cell Technology [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Texans for Stem Cell Research Learn for Life: KXAN Coverage Aired August 16th, 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT - Dr Lanza - Hermangioblast program - Advanced cell technology [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Anticipating the Next Decade of the Genome - Francis Collins, Director of NIH [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- New Epilepsy Treatment Under Study For Seizures - Part 1 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Thank You For Trevor Raborn [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- CBLI Breaking News [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem cell medical breakthrough? [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- NIST Colloquium Series: Next Generation Neural Implants [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Alan Lewis: Embryonic Stem Cell Therapies for diabetes [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2011 Predictions for Hair Transplant Developments | Arocha Hair Restoration [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Healthbeat - Stem Cell Research [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Living With ALS [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Revolutionary New Potential Treatment for Glioblastoma... [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Lyme Disease: Challenges and Innovations [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2010: Cord blood saving lives [CNN: 5-30-2011] [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Biotechnology, Diagnostics, and Genomics: Panel Discussion [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Pharmacogenomics [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Brickheads - Osteobots Practice Skit.mpg [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A veteran lives with ALS [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Healthy Body = Functional Body. Hollywood Look Side Effect: Healthy Function [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 2009 Flu Summit: Opening Remarks [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Cord Blood Breakthrough [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- SENS5 - Leucocyte transfusions as a novel immunotherapy for cancer patients [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Lymphoma Drug SGN-35 - The Nebraska Medical Center [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- ACell Hair Restoration with Dr. Gary Hitzig and Dr. Amiya Prasad - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Hans Keirstead: Developing therapies based on embryonic stem cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- NJN News Healthwatch Report - Cornea Treatment Study - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- HIV/AIDS may be prevented by new lubricant - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- MFIII Switzerland PE Sheep Placenta Glandular therapy Study - Client Interviews - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- Love Diabetes: BCG and Noncompliant Patients - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Dr. Alimorad Farshchian statement on embryonic stem cells - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- StemCellTV Daily Report-October 29, 2011 - Video [Last Updated On: October 30th, 2011] [Originally Added On: October 30th, 2011]
- Stephen McKenna MD - 8 - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- ALS Stem Cell Trial at Emory - Video [Last Updated On: November 22nd, 2011] [Originally Added On: November 22nd, 2011]
- Target Product Profile: Ellen Feigal - 2011 CIRM Grantee Meeting - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- Monoclonal Antibodies: Stanford Academia-Industry Collaboration - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- Parkinson's Disease Guidelines (Part 2) - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Macular Degeneration Drugs - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- BrainStorm Cell Therapeutics (OTCBB:BCLI) Has Potentially Developed A Treatment For ALS [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Stemedica Cell Technologies - Documentary - Video [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- (GMCR, STEM, DSCO) CRWENewswire.com Stocks In Action - Video [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Stem Cells Regrow Healthy Heart Muscle In Heart Attack Patients [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer Trial With I-124-CLR1404 (Light) Cancer ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress and New Initiatives [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Novelos Therapeutics and Academic Collaborators Have Three Abstracts Accepted for Presentation at 2012 AACR Annual ... [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 [Last Updated On: March 6th, 2012] [Originally Added On: March 6th, 2012]
- Will StemCells Walk The Talk? [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Internationally Recognized Leukemia Physician and Researcher to Lead Sylvester Comprehensive Cancer Center [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Criminal investigation after patient dies at office of doctor linked to stem cell [Last Updated On: March 9th, 2012] [Originally Added On: March 9th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Brain Cancer Trial with I-124-CLR1404 (LIGHT) Cancer ... [Last Updated On: March 15th, 2012] [Originally Added On: March 15th, 2012]
- Vitro Biopharma Receives Approval for Presentation to the International Society for Cellular Therapy [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Looking for Innovative Small-Cap Biotech Companies: George Zavoico [Last Updated On: March 26th, 2012] [Originally Added On: March 26th, 2012]
- Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of ... [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- Gentium Reports Fourth Quarter and Year End 2011 Financial Results [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- Basketball’s influence on stem cell treatments in sports medicine [Last Updated On: March 30th, 2012] [Originally Added On: March 30th, 2012]
- Cardium Announces U.S. Market Introduction of Excellagen™ [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult ... [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile ... [Last Updated On: April 1st, 2012] [Originally Added On: April 1st, 2012]
- SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC [Last Updated On: April 19th, 2012] [Originally Added On: April 19th, 2012]
- Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem's ERC Technology and Joins Advisory Board [Last Updated On: April 26th, 2012] [Originally Added On: April 26th, 2012]